U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H20NO3PS
Molecular Weight 361.395
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FOSTEDIL

SMILES

CCOP(=O)(CC1=CC=C(C=C1)C2=NC3=CC=CC=C3S2)OCC

InChI

InChIKey=FVYRUSCZCWSFLT-UHFFFAOYSA-N
InChI=1S/C18H20NO3PS/c1-3-21-23(20,22-4-2)13-14-9-11-15(12-10-14)18-19-16-7-5-6-8-17(16)24-18/h5-12H,3-4,13H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C18H20NO3PS
Molecular Weight 361.395
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Fostedil (KB-944) is a phosphonic acid derivative with potent vasodilator activity. KB-944 has been demonstrated to produce long lasting coronary vasodilator and hypotensive effects in conscious and anesthetized dogs; increase coronary blood flow in isolated, blood perfused heart preparations of dogs; and reduce systemic pressure in conscious normotensive and hypertensive rats. Slow channel calcium entry blockade is thought to contribute to the vasodilator activity of KB-944. Fostedil is longer acting in hypertensive animals than either nifedipine or diltiazem suggesting a potential clinical advantage for this compound. Unexpectedly, fostedil was shown to produce atrial fibrillation in 3 of 10 hypertensive patients in a placebo controlled study. Fostedil had been in phase II clinical trials for the treatment of angina pectoris. However, this research has been discontinued.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Cmax

ValueDoseCo-administeredAnalytePopulation
2.33 μg/mL
12 mg/kg single, oral
FOSTEDIL plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
17.33 μg × h/mL
12 mg/kg single, oral
FOSTEDIL plasma
Homo sapiens
25.88 μg × h/mL
12 mg/kg single, intravenous
FOSTEDIL plasma
Canis lupus

T1/2

ValueDoseCo-administeredAnalytePopulation
8.45 h
12 mg/kg single, oral
FOSTEDIL plasma
Homo sapiens
6.42 h
12 mg/kg single, intravenous
FOSTEDIL plasma
Canis lupus

Funbound

ValueDoseCo-administeredAnalytePopulation
4%
12 mg/kg single, oral
FOSTEDIL plasma
Homo sapiens

Doses

AEs

PubMed

Sample Use Guides

In Vivo Use Guide
100 mg once daily
Route of Administration: Oral
In Vitro Use Guide
Fostedil (10(-5)-10(-4) M) decreased the action potential duration measured at 30% repolarization and hyperpolarized the resting membrane potential in ventricular trabeculae of the dog heart. In single ventricular cells of the guinea-pig heart, Fostedil (10(-4) M) abolished the slow inward current and produced an outward shift of the late current measured at the end of 200 msec clamp pulse.
Substance Class Chemical
Record UNII
D41WS786UL
Record Status Validated (UNII)
Record Version